LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxiainducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data

Category Systematic review
JournalJournal of Clinical Oncology
Year 2022
This article has no abstract
Epistemonikos ID: 99e8e7610b7c95bd42ba8030101c44e9472550fb
First added on: Feb 14, 2025